Mechanisms of neurocognitive dysfunction and therapeutic considerations in tuberous sclerosis complex

Peter Tsai, Mustafa Sahin

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Purpose of review: Mendelian disorders that affect cognition provide a unique opportunity to study the mechanisms of neurodevelopmental disorders through the examination of genetic defects in animals and development of hypotheses that can be tested in human beings. Tuberous sclerosis complex (TSC) is a genetic disease that presents with epilepsy, autism, and intellectual disability. Here we review recent advances in our understanding of TSC pathogenesis and signaling pathways that may be modulated to treat the neurological symptoms. Recent findings: Accumulating evidence suggests that TSC patients have nontuber abnormalities that contribute to the development of the neurological phenotype- in particular, disorganization of axon tracts and deficient myelination. TSC mouse models have failed to replicate the human neuropathology entirely, but have shed light on the cellular abnormalities and the neurobehavioral phenotypes. Most importantly, cell culture and animal models have identified the mTORC1 pathway as a therapeutic target in this disease. Summary: Preclinical data strongly suggest that TSC is a disease of abnormal neuronal connectivity. The high incidence of neurodevelopmental deficits, early detection of the disease in very young ages, and availability of mTORC1 inhibitors make TSC a model for other Mendelian disorders of neurocognition and an avenue for the mechanism-based treatment trials of neurodevelopmental disorders.

Original languageEnglish (US)
Pages (from-to)106-113
Number of pages8
JournalCurrent Opinion in Neurology
Volume24
Issue number2
DOIs
StatePublished - Apr 2011

Fingerprint

Tuberous Sclerosis
Cognition Disorders
Therapeutics
Phenotype
Inborn Genetic Diseases
Autistic Disorder
Intellectual Disability
Axons
Early Diagnosis
Epilepsy
Animal Models
Cell Culture Techniques
Incidence

Keywords

  • autism
  • DTI
  • mTOR
  • translation

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Mechanisms of neurocognitive dysfunction and therapeutic considerations in tuberous sclerosis complex. / Tsai, Peter; Sahin, Mustafa.

In: Current Opinion in Neurology, Vol. 24, No. 2, 04.2011, p. 106-113.

Research output: Contribution to journalArticle

@article{79ad5f672ad943d5998d4e01e27957e2,
title = "Mechanisms of neurocognitive dysfunction and therapeutic considerations in tuberous sclerosis complex",
abstract = "Purpose of review: Mendelian disorders that affect cognition provide a unique opportunity to study the mechanisms of neurodevelopmental disorders through the examination of genetic defects in animals and development of hypotheses that can be tested in human beings. Tuberous sclerosis complex (TSC) is a genetic disease that presents with epilepsy, autism, and intellectual disability. Here we review recent advances in our understanding of TSC pathogenesis and signaling pathways that may be modulated to treat the neurological symptoms. Recent findings: Accumulating evidence suggests that TSC patients have nontuber abnormalities that contribute to the development of the neurological phenotype- in particular, disorganization of axon tracts and deficient myelination. TSC mouse models have failed to replicate the human neuropathology entirely, but have shed light on the cellular abnormalities and the neurobehavioral phenotypes. Most importantly, cell culture and animal models have identified the mTORC1 pathway as a therapeutic target in this disease. Summary: Preclinical data strongly suggest that TSC is a disease of abnormal neuronal connectivity. The high incidence of neurodevelopmental deficits, early detection of the disease in very young ages, and availability of mTORC1 inhibitors make TSC a model for other Mendelian disorders of neurocognition and an avenue for the mechanism-based treatment trials of neurodevelopmental disorders.",
keywords = "autism, DTI, mTOR, translation",
author = "Peter Tsai and Mustafa Sahin",
year = "2011",
month = "4",
doi = "10.1097/WCO.0b013e32834451c4",
language = "English (US)",
volume = "24",
pages = "106--113",
journal = "Current Opinion in Neurology",
issn = "1350-7540",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Mechanisms of neurocognitive dysfunction and therapeutic considerations in tuberous sclerosis complex

AU - Tsai, Peter

AU - Sahin, Mustafa

PY - 2011/4

Y1 - 2011/4

N2 - Purpose of review: Mendelian disorders that affect cognition provide a unique opportunity to study the mechanisms of neurodevelopmental disorders through the examination of genetic defects in animals and development of hypotheses that can be tested in human beings. Tuberous sclerosis complex (TSC) is a genetic disease that presents with epilepsy, autism, and intellectual disability. Here we review recent advances in our understanding of TSC pathogenesis and signaling pathways that may be modulated to treat the neurological symptoms. Recent findings: Accumulating evidence suggests that TSC patients have nontuber abnormalities that contribute to the development of the neurological phenotype- in particular, disorganization of axon tracts and deficient myelination. TSC mouse models have failed to replicate the human neuropathology entirely, but have shed light on the cellular abnormalities and the neurobehavioral phenotypes. Most importantly, cell culture and animal models have identified the mTORC1 pathway as a therapeutic target in this disease. Summary: Preclinical data strongly suggest that TSC is a disease of abnormal neuronal connectivity. The high incidence of neurodevelopmental deficits, early detection of the disease in very young ages, and availability of mTORC1 inhibitors make TSC a model for other Mendelian disorders of neurocognition and an avenue for the mechanism-based treatment trials of neurodevelopmental disorders.

AB - Purpose of review: Mendelian disorders that affect cognition provide a unique opportunity to study the mechanisms of neurodevelopmental disorders through the examination of genetic defects in animals and development of hypotheses that can be tested in human beings. Tuberous sclerosis complex (TSC) is a genetic disease that presents with epilepsy, autism, and intellectual disability. Here we review recent advances in our understanding of TSC pathogenesis and signaling pathways that may be modulated to treat the neurological symptoms. Recent findings: Accumulating evidence suggests that TSC patients have nontuber abnormalities that contribute to the development of the neurological phenotype- in particular, disorganization of axon tracts and deficient myelination. TSC mouse models have failed to replicate the human neuropathology entirely, but have shed light on the cellular abnormalities and the neurobehavioral phenotypes. Most importantly, cell culture and animal models have identified the mTORC1 pathway as a therapeutic target in this disease. Summary: Preclinical data strongly suggest that TSC is a disease of abnormal neuronal connectivity. The high incidence of neurodevelopmental deficits, early detection of the disease in very young ages, and availability of mTORC1 inhibitors make TSC a model for other Mendelian disorders of neurocognition and an avenue for the mechanism-based treatment trials of neurodevelopmental disorders.

KW - autism

KW - DTI

KW - mTOR

KW - translation

UR - http://www.scopus.com/inward/record.url?scp=79953030273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953030273&partnerID=8YFLogxK

U2 - 10.1097/WCO.0b013e32834451c4

DO - 10.1097/WCO.0b013e32834451c4

M3 - Article

VL - 24

SP - 106

EP - 113

JO - Current Opinion in Neurology

JF - Current Opinion in Neurology

SN - 1350-7540

IS - 2

ER -